1. Xultophy, developed by Plainsboro, N.J.-based Novo Nordisk, is a once-daily injection intended to help adults with type 2 diabetes achieve better glycemic control.
2. Paris, France-based Sanofi earned approval for Soliqua — also a once-daily injection for adults with type 2 diabetes.
3. The immunotherapy drug Darzalex can now be used in combination with two other treatment regimens for patients with multiple myeloma.
4. NanoBone SBX Putty is a synthetic bone replacement material intended to stimulate quicker bone formation.
5. The Countour Next One blood glucose monitoring system features a blood glucose smart meter, which can connect to an app on a patient’s mobile device to store and analyze blood glucose measurements.
More articles on supply chain:
4 things to know about how the patient’s voice is changing medical research
Cargo carrier pilots go on strike — disrupt shipments for DHL, Amazon
Ascensia Diabetes Care earns FDA clearance for new glucose monitoring system
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.